142 related articles for article (PubMed ID: 33721445)
1. Efficacy of bevacizumab combined with temozolomide dose-dense regimen on recurrent glioma.
Li J; Huang W; Piao M; Liu Z; Ji S; Xue J; Zhu X
J BUON; 2021; 26(1):145-151. PubMed ID: 33721445
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic effect of thalidomide combined with temozolomide and three-dimensional conformal radiotherapy for patients with high-grade gliomas after operation.
Sui L; Li Y; Xu Z; Shen X
J BUON; 2020; 25(6):2608-2615. PubMed ID: 33455103
[TBL] [Abstract][Full Text] [Related]
3. Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer.
Wu M; Gong J; Yu W; Geng J; Zeng L; Kong X
J BUON; 2020; 25(4):1814-1820. PubMed ID: 33099918
[TBL] [Abstract][Full Text] [Related]
4. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide chemotherapy combined with radiotherapy versus radiotherapy alone after surgery in patients with high-risk low-grade gliomas.
Hou Y; Huan Y; Zhang Y; Liu X; Li Y
J BUON; 2021; 26(3):977-983. PubMed ID: 34268962
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.
Han SJ; Rolston JD; Molinaro AM; Clarke JL; Prados MD; Chang SM; Berger MS; DeSilva A; Butowski NA
Neuro Oncol; 2014 Sep; 16(9):1255-62. PubMed ID: 24670608
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
8. Observation versus radiotherapy with or without temozolomide in postoperative WHO grade II high-risk low-grade glioma: a retrospective cohort study.
Wang J; Yan L; Ai P; He Y; Guan H; Wei Z; He L; Mu X; Liu Y; Peng X
Neurosurg Rev; 2021 Jun; 44(3):1447-1455. PubMed ID: 32529528
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
[TBL] [Abstract][Full Text] [Related]
10. Postmortem study of organ-specific toxicity in glioblastoma patients treated with a combination of temozolomide, irinotecan and bevacizumab.
Lu G; Zhu P; Rao M; Linendoll N; Buja LM; Bhattacharjee MB; Brown RE; Ballester LY; Tian X; Pilichowska M; Wu JK; Hergenroeder GW; Glass WF; Chen L; Zhang R; Pillai AK; Hunter RL; Zhu JJ
J Neurooncol; 2022 Oct; 160(1):221-231. PubMed ID: 36203027
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Omuro A; Chan TA; Abrey LE; Khasraw M; Reiner AS; Kaley TJ; Deangelis LM; Lassman AB; Nolan CP; Gavrilovic IT; Hormigo A; Salvant C; Heguy A; Kaufman A; Huse JT; Panageas KS; Hottinger AF; Mellinghoff I
Neuro Oncol; 2013 Feb; 15(2):242-50. PubMed ID: 23243055
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas.
Peters KB; Lipp ES; Miller E; Herndon JE; McSherry F; Desjardins A; Reardon DA; Friedman HS
J Neurooncol; 2018 Apr; 137(2):349-356. PubMed ID: 29264836
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Bevacizumab Combined with Albumin-Bound Paclitaxel in the Treatment of Platinum-Resistant Recurrent Ovarian Cancer.
Liu B; An R; Yu J
J BUON; 2019; 24(6):2303-2309. PubMed ID: 31983098
[TBL] [Abstract][Full Text] [Related]
15. Improvement of health related quality of life in patients with recurrent glioma treated with bevacizumab plus daily temozolomide as the salvage therapy.
Liu Y; Feng F; Ji P; Liu B; Ge S; Yang C; Lou M; Liu J; Li B; Gao G; Qu Y; Wang L
Clin Neurol Neurosurg; 2018 Jun; 169():64-70. PubMed ID: 29631109
[TBL] [Abstract][Full Text] [Related]
16. Effect of low-dose bevacizumab on health-related quality of life in patients with recurrent high-grade glioma: A retrospective clinical study.
Liao Y; Bai X; Cao Y; Zhang M
J Clin Neurosci; 2024 Feb; 120():196-203. PubMed ID: 38277995
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.
Nagane M; Nishikawa R; Narita Y; Kobayashi H; Takano S; Shinoura N; Aoki T; Sugiyama K; Kuratsu J; Muragaki Y; Sawamura Y; Matsutani M
Jpn J Clin Oncol; 2012 Oct; 42(10):887-95. PubMed ID: 22844129
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
19. Clinical study of apatinib plus temozolomide for the treatment of recurrent high-grade gliomas.
Yao H; Liu J; Zhang C; Shao Y; Li X; Feng M; Wang X; Gan W; Zhou Y; Huang Y
J Clin Neurosci; 2021 Aug; 90():82-88. PubMed ID: 34275586
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of thalidomide combined with temozolomide and three-dimensional conformal radiotherapy for patients with high-grade gliomas after operation.
Sui L; Li Y; Xu Z; Shen X
J BUON; 2021; 26(1):2608-2615. PubMed ID: 33721435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
